12 October 2023
12 October 2023
Ozempic is approved in the US, Canada, EU, Japan, and Australia as a treatment for type 2 diabetes.
Biomarin and CSL Behring’s haemophilia gene therapies have boosted innovation in the field, but assessing their cost effectiveness is less than straightforward.
GlobalData analyst Wafaa Hasan discusses key topics around cybersecurity for the pharmaceutical industry.
Topline results from an ongoing Phase IIa study with SLS009 are expected by the end of the year.
The New Jersey-based company has announced that it has acquired a number of assets from California-based Federation Bio, allowing it to carve out space in the therapeutics market.
The collaboration aims to boost open innovation hub SakuLab-Tsukaba at Astellas’ Tsukuba Research Centre.
SparX’s monoclonal antibody was used to develop the Claudin 18.2 tumour-specific antigen targeting CAR-iNKT cell therapy.
MinervaX is currently conducting Phase II trials of the prophylactic maternal vaccine against group B streptococcus bacterial infections.
Join us on October 17th, as Boris Baňas and Jan Storch discuss the challenges of sourcing certified cannabis for clinical trials and delve into CB21 Pharma's cannabis-derived product portfolio.
As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. KOLs remain hopeful that these companies will uncover a class of drugs that works effectively to slow or modify the disease course. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs.
Give your business an edge with our leading industry insights.
